These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

167 related articles for article (PubMed ID: 33350168)

  • 1. Validation of International Working Group response criteria in higher-risk myelodysplastic syndromes: A report on behalf of the MDS Clinical Research Consortium.
    Komrokji RS; Al Ali NH; Sallman D; Padron E; DeZern AE; Barnard J; Roboz GJ; Garcia-Manero G; List A; Steensma DP; Sekeres MA
    Cancer Med; 2021 Jan; 10(2):447-453. PubMed ID: 33350168
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Evaluating complete remission with partial hematologic recovery (CRh) as a response criterion in myelodysplastic syndromes (MDS).
    Brunner AM; Gavralidis A; Ali NA; Hunter A; Komrokji R; Zeidan A; Sallman DA
    Blood Cancer J; 2022 Nov; 12(11):153. PubMed ID: 36379923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A phase 1b study of venetoclax and azacitidine combination in patients with relapsed or refractory myelodysplastic syndromes.
    Zeidan AM; Borate U; Pollyea DA; Brunner AM; Roncolato F; Garcia JS; Filshie R; Odenike O; Watson AM; Krishnadasan R; Bajel A; Naqvi K; Zha J; Cheng WH; Zhou Y; Hoffman D; Harb JG; Potluri J; Garcia-Manero G
    Am J Hematol; 2023 Feb; 98(2):272-281. PubMed ID: 36309981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Acute myeloid leukemia or myelodysplastic syndrome with chromosome 17 abnormalities and long-term outcomes with or without hematopoietic stem cell transplantation.
    Britt A; Mohyuddin GR; McClune B; Singh A; Lin T; Ganguly S; Abhyankar S; Shune L; McGuirk J; Skikne B; Godwin A; Pessetto Z; Golem S; Divine C; Dias A
    Leuk Res; 2020 Aug; 95():106402. PubMed ID: 32590108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcome of patients with low-risk and intermediate-1-risk myelodysplastic syndrome after hypomethylating agent failure: a report on behalf of the MDS Clinical Research Consortium.
    Jabbour EJ; Garcia-Manero G; Strati P; Mishra A; Al Ali NH; Padron E; Lancet J; Kadia T; Daver N; O'Brien S; Steensma DP; Sekeres MA; Gore SD; Dezern A; Roboz GJ; List AF; Kantarjian HM; Komrokji RS
    Cancer; 2015 Mar; 121(6):876-82. PubMed ID: 25410759
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Impact of achievement of complete cytogenetic response on outcome in patients with myelodysplastic syndromes treated with hypomethylating agents.
    Jabbour E; Strati P; Cabrero M; O'Brien S; Ravandi F; Bueso-Ramos C; Wei Q; Hu J; Abi Aad S; Short NJ; Dinardo C; Daver N; Kadia T; Wierda W; Wei Y; Colla S; Borthakur G; Cortes J; Estrov Z; Kantarjian H; Garcia-Manero G
    Am J Hematol; 2017 Apr; 92(4):351-358. PubMed ID: 28076892
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective study of autologous bone marrow or peripheral blood stem cell transplantation after intensive chemotherapy in myelodysplastic syndromes. Groupe Français des Myélodysplasies. Group Ouest-Est d'étude des Leucémies aiguës myéloïdes.
    Wattel E; Solary E; Leleu X; Dreyfus F; Brion A; Jouet JP; Hoang-Ngoc L; Maloisel F; Guerci A; Rochant H; Gratecos N; Casassus P; Janvier M; Brice P; Lepelley P; Fenaux P
    Leukemia; 1999 Apr; 13(4):524-9. PubMed ID: 10214857
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.
    de Witte T; Suciu S; Verhoef G; Labar B; Archimbaud E; Aul C; Selleslag D; Ferrant A; Wijermans P; Mandelli F; Amadori S; Jehn U; Muus P; Boogaerts M; Zittoun R; Gratwohl A; Zwierzina H; Hagemeijer A; Willemze R
    Blood; 2001 Oct; 98(8):2326-31. PubMed ID: 11588026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Upfront transplantation may have better outcomes than pretransplant cytoreductive therapy for treating patients with MDS-EB-1 or MDS-EB-2.
    Chen Y; Huang F; Xuan L; Zhang Y; Fan Z; Xu N; Zhao K; Xu J; Liu H; Shi P; Wang Z; Sun J; Zheng W; Dai M; Liu Q
    Int J Cancer; 2021 Sep; 149(5):1109-1120. PubMed ID: 33899230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of Intensive Chemotherapy and Hypomethylating Agents before Allogeneic Stem Cell Transplantation for Advanced Myelodysplastic Syndromes: A Study of the Myelodysplastic Syndrome Subcommittee of the Chronic Malignancies Working Party of the European Society for Blood and Marrow Transplant Research.
    Potter VT; Iacobelli S; van Biezen A; Maertens J; Bourhis JH; Passweg JR; Yakhoub-Agha I; Tabrizi R; Bay JO; Chevallier P; Chalandon Y; Huynh A; Cahn JY; Ljungman P; Craddock C; Lenhoff S; Russell NH; Fegueux N; Socié G; Bruno B; Meijer E; Mufti GJ; de Witte T; Robin M; Kröger N
    Biol Blood Marrow Transplant; 2016 Sep; 22(9):1615-1620. PubMed ID: 27264633
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Efficacy and safety of venetoclax combined with hypomethylating agents in the treatment of 83 patients with higher-risk myelodysplastic syndromes].
    Liu L; He F; Xu Y; Li T; Li YF; Tang P; Sun L
    Zhonghua Xue Ye Xue Za Zhi; 2024 Mar; 45(3):277-283. PubMed ID: 38716600
    [No Abstract]   [Full Text] [Related]  

  • 12. Outcome of patients with high risk Myelodysplastic Syndrome (MDS) and advanced Chronic Myelomonocytic Leukemia (CMML) treated with decitabine after azacitidine failure.
    Harel S; Cherait A; Berthon C; Willekens C; Park S; Rigal M; Brechignac S; Thépot S; Quesnel B; Gardin C; Adès L; Fenaux P; Braun T
    Leuk Res; 2015 May; 39(5):501-4. PubMed ID: 25735917
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Improving Revised International Prognostic Scoring System Pre-Allogeneic Stem Cell Transplantation Does Not Translate Into Better Post-Transplantation Outcomes for Patients with Myelodysplastic Syndromes: A Single-Center Experience.
    Alzahrani M; Power M; Abou Mourad Y; Barnett M; Broady R; Forrest D; Gerrie A; Hogge D; Nantel S; Sanford D; Song K; Sutherland H; Toze C; Nevill T; Narayanan S
    Biol Blood Marrow Transplant; 2018 Jun; 24(6):1209-1215. PubMed ID: 29474870
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed AML and MDS after allogeneic stem cell transplantation with decitabine and DLI-a retrospective multicenter analysis on behalf of the German Cooperative Transplant Study Group.
    Schroeder T; Rautenberg C; Krüger W; Platzbecker U; Bug G; Steinmann J; Klein S; Hopfer O; Nachtkamp K; Kondakci M; Geyh S; Haas R; Germing U; Bornhäuser M; Kobbe G
    Ann Hematol; 2018 Feb; 97(2):335-342. PubMed ID: 29151133
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Outcomes of patients with myelodysplastic syndromes who achieve stable disease after treatment with hypomethylating agents.
    Nazha A; Sekeres MA; Garcia-Manero G; Barnard J; Al Ali NH; Roboz GJ; Steensma DP; DeZern AE; Zimmerman C; Jabbour EJ; Zell K; List AF; Kantarjian HM; Maciejewski JP; Komrokji RS;
    Leuk Res; 2016 Feb; 41():43-7. PubMed ID: 26777537
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Discontinuation of hypomethylating agent therapy in patients with myelodysplastic syndromes or acute myelogenous leukemia in complete remission or partial response: retrospective analysis of survival after long-term follow-up.
    Cabrero M; Jabbour E; Ravandi F; Bohannan Z; Pierce S; Kantarjian HM; Garcia-Manero G
    Leuk Res; 2015 May; 39(5):520-4. PubMed ID: 25828745
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Treatment with 5-Azacytidine improves clinical outcome in high-risk MDS patients in the 'real life' setting: A single center observational study.
    Papageorgiou SG; Vasilatou D; Kontos CK; Foukas P; Kefala M; Ioannidou ED; Bouchla A; Bazani E; Dimitriadis G; Pappa V
    Hematology; 2016 Jan; 21(1):34-41. PubMed ID: 26218077
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Update of the decitabine experience in higher risk myelodysplastic syndrome and analysis of prognostic factors associated with outcome.
    Kantarjian HM; O'Brien S; Shan J; Aribi A; Garcia-Manero G; Jabbour E; Ravandi F; Cortes J; Davisson J; Issa JP
    Cancer; 2007 Jan; 109(2):265-73. PubMed ID: 17133405
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pre-transplant hypomethylating agents do not influence post-transplant survival in myelodysplastic syndrome.
    Modi D; Kim S; Singh V; Ayash L; Alavi A; Ratanatharathorn V; Uberti JP; Deol A
    Leuk Lymphoma; 2019 Nov; 60(11):2762-2770. PubMed ID: 31010370
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A Phase 2 study of combination therapy with arsenic trioxide and gemtuzumab ozogamicin in patients with myelodysplastic syndromes or secondary acute myeloid leukemia.
    Sekeres MA; Maciejewski JP; Erba HP; Afable M; Englehaupt R; Sobecks R; Advani A; Seel S; Chan J; Kalaycio ME
    Cancer; 2011 Mar; 117(6):1253-61. PubMed ID: 20960521
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.